ABBISKO-B (02256) announced that its novel selective CDK4 inhibitor ABSK192 monotherapy and combination therapy preclinical research results were presented at the 2026 ENA Conference
ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics), announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster format at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference).
ABBISKO-B (02256) announced that its subsidiary Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics) announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster form at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference). This study was selected for the Late-Breaking Abstracts (LBA) program, and Dr. Zhang Nannan, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented on-site the monotherapy activity and broad combination therapy potential of ABSK192 in HR+/HER2- breast cancer models.
Related Articles

Breaking SpaceX's record! Anthropic (ANT.US) IPO raises $81.3 billion, priced above the guidance range, debuts on Nasdaq tonight

JD HEALTH (06618): Trustee purchased a total of 10.0534 million shares under the share award scheme

HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Breaking SpaceX's record! Anthropic (ANT.US) IPO raises $81.3 billion, priced above the guidance range, debuts on Nasdaq tonight

JD HEALTH (06618): Trustee purchased a total of 10.0534 million shares under the share award scheme

HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics






